Nuclear endocrinology as a monitoring tool

Seminars in Nuclear Medicine

Volumn 31, Issue 3, 2001, Pages 238-250

  Krausz, Yodphat ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; PENTETATE INDIUM IN 111; PEPTIDE; THALLIUM 201; THYROTROPIN;

ADRENAL CANCER; ADRENAL CORTEX TUMOR; ANTIGEN ANTIBODY COMPLEX; CANCER DIAGNOSIS; CANCER STAGING; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ENDOCRINE TUMOR; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHEOCHROMOCYTOMA; RADIOIODINATION; RECURRENT CANCER; REVIEW; THYROID CARCINOMA; TUMOR LOCALIZATION;

EID: 0034972908     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.23530     Document Type: Article

References (95)

1. Papillary and follicular thyroid carcinoma
2. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance
3. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma
4. Gamma camera-mounted anatomical x-ray tomography: Technology, system characteristics and first images
5. Nuclear imaging in the management of thyroid carcinoma
6. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II Study)
7. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma
8. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer
9. Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma
10. Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50
11. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer
12. Thallium-201 uptake with negative iodine-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma
13. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer
14. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan
15. Value of FDG-PET in papillary thyroid carcinoma with negative 131I whole-body scan
16. Technetium-99m-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid
17. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
18. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients
19. Thyroid carcinoma metastasis to the choroid responding to systemic I-131 therapy
20. 131I therapy for elevated thyroglobulin levels
21. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma
22. Radioiodine-131 therapy for well-differentiated thyroid cancer-A quantitative radiation dosimetric approach: Outcome and validation in 85 patients
23. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer
24. Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results
25. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma
26. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems
27. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid
28. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: A comparative study
29. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization
30. Recurrent medullary carcinoma of the thyroid demonstrated by thallium-201 scintigraphy
31. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid
32. Imaging of medullary thyroid carcinoma with 131I-MIBG
33. Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid
34. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma
35. Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma
36. In vitro detection of somatostatin receptors in human tumors
37. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings
38. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scint imaging in neural crest tumors
39. In vivo somatostatin receptor imaging in medullary thyroid carcinoma
40. Somatostatin-receptor imaging of medullary thyroid carcinoma
41. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid
42. Diagnostic applications of radiolabeled peptides in nuclear endocrinology
43. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
44. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer
45. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas
46. Anticarcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
47. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study
48. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas
49. Targeting of cholecystokinin-B/gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin
50. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI
51. Adrenal cortical and medullary imaging
52. Unusual causes of I-131 metaiodobenzylguanidine uptake in non-neural crest tissue
53. Current concepts on the diagnostic use of MIBG in children
54. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma
55. Comparison of radiolabeled octreotide and metaiodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma
56. Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET
57. PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma
58. Treatment planning for 131I-MIBG radiotherapy of neural crest tumours using 124I-MIBG positron emission tomography
59. Nuclear medicine imaging of pheochromocytoma and neuroblastoma
60. Specificity of radioiodinated MIBG for neural crest tumors in childhood
61. Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector
62. Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging
63. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma
64. Nuclear medicine therapy of neuroblastoma
65. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
66. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome
67. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy
68. Integrated imaging of adrenal disease
69. Adrenal radiology: Distinguishing benign from malignant adrenal masses
70. Adrenal cortical neoplasms. A study of 56 cases
71. In vitro and in vivo primate evaluation of carbon-11-metomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors
72. PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer 11C-metomidate
73. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
74. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy
75. The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children
76. FDG-PET in adrenocortical carcinoma
77. The visualization of gastroenteropancreatic endocrine tumors
78. In vitro and in vivo detection of somatostatin receptors in human malignant tissues
79. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues
80. In111-octreotide scintigraphy in oncology
81. Intraoperative gamma probe detection of neuroendocrine tumors
82. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients
83. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors
84. Somatostatin analogue scintigraphy in carcinoid tumours
85. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging
86. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results
87. Somatostatin-receptor scintigraphy of subcutaneous and thyroid metastases from bronchial carcinoid
88. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management
89. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors
90. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas
91. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors
92. Metastatic carcinoid tumors and the malignant carcinoid syndrome
93. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors
94. Yttrium-90-labelled somatostatin-analogue for cancer treatment
95. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues